JPMorgan Chase & Co. Issues Pessimistic Forecast for ICON Public (NASDAQ:ICLR) Stock Price

ICON Public (NASDAQ:ICLR) had its price objective cut by JPMorgan Chase & Co. from $280.00 to $265.00 in a report released on Monday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other analysts also recently weighed in on ICLR. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Royal Bank of Canada reissued an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a research report on Wednesday, January 15th. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. The Goldman Sachs Group cut their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, Citigroup cut their price objective on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ICON Public has a consensus rating of “Moderate Buy” and an average price target of $285.75.

ICON Public Stock Up 1.6 %

NASDAQ:ICLR opened at $196.41 on Monday. The firm’s 50-day moving average price is $208.20 and its 200-day moving average price is $256.12. The company has a market capitalization of $16.20 billion, a PE ratio of 21.90, a P/E/G ratio of 1.79 and a beta of 1.19. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public has a 1-year low of $183.38 and a 1-year high of $347.72.

Hedge Funds Weigh In On ICON Public

Institutional investors have recently made changes to their positions in the business. Sierra Ocean LLC bought a new position in shares of ICON Public in the 4th quarter worth approximately $29,000. Park Place Capital Corp lifted its stake in shares of ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after purchasing an additional 166 shares during the period. Private Trust Co. NA lifted its stake in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after purchasing an additional 82 shares during the period. GAMMA Investing LLC increased its holdings in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares during the period. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.